Irisin: A new molecular marker and target in metabolic disorder

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Chen, Jia Qi ^a,b   Huang, Yue Ye ^a   Gusdon, Aaron M ^c   Qu, Shen ^a,b  

^a TONGJI UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Irisin; Metabolic diseases; Obesity

Indexed keywords

IRISIN; BIOLOGICAL MARKER; FIBRONECTIN;

GLUCOSE HOMEOSTASIS; HUMAN; METABOLIC DISORDER; METABOLIC SYNDROME X; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; REVIEW; ANIMAL; DIABETES MELLITUS; METABOLISM;

ANIMALS; BIOMARKERS; DIABETES MELLITUS; FIBRONECTINS; HUMANS; METABOLIC DISEASES; MOLECULAR TARGETED THERAPY; OBESITY;

EID: 84949115395     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-14-2     Document Type: Review

References (41)

1. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund K, Gygi SP, Spiegelman BM: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012,481(7382):463-8. 10.1038/nature10777
2. Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, Giang AH, Khandekar M, Virtanen KA, Nuutila P, Schaart G, Huang K, Tu H, van Marken LW, Hoeks J, Enerback S, Schrauwen P, Spiegelman BM: Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012,150(2):366-76. 10.1016/j.cell.2012.05.016
3. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS: FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012,61(12):1725-38. 10.1016/j.metabol.2012.09.002
4. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF: Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-correlation with body mass index. Peptides 2013, 39:125-30.
5. Pardo M, Crujeiras AB, Amil M, Aguera Z, Jimenez-Murcia S, Banos R, Botella C, de la Torre R, Estivill X, Fagundo AB, Fernandez-Real JM, Fernandez-Garcia JC, Fruhbeck G, Gomez-Ambrosi J, Rodriguez R, Tinahones FJ, Fernandez-Aranda F, Casanueva FF: Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol 2014, 2014:857270.
6. Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC: Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013,27(4):365-9. 10.1016/j.jdiacomp.2013.03.002
7. Liu JJ, Liu S, Wong MD, Tan CS, Tavintharan S, Sum CF, Lim SC: Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complications 2014,28(2):208-13. 10.1016/j.jdiacomp.2013.09.011
8. Crujeiras AB, Pardo M, Arturo RR, Navas-Carretero S, Zulet MA, Martinez JA, Casanueva FF: Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Hum Biol 2014,26(2):198-207. 10.1002/ajhb.22493
9. Park KH, Zaichenko L, Peter P, Davis CR, Crowell JA, Mantzoros CS: Diet quality is associated with circulating C-reactive protein but not irisin levels in humans. Metabolism 2014,63(2):233-41. 10.1016/j.metabol.2013.10.011
10. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernandez-Real JM: Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013,98(4):E769-78. 10.1210/jc.2012-2749
11. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG: Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013,100(1):96-101. 10.1016/j.diabres.2013.01.007
12. Sanchis-Gomar F, Alis R, Pareja-Galeano H, Sola E, Victor VM, Rocha M, Hernandez-Mijares A, Romagnoli M: Circulating irisin levels are not correlated with BMI, age, and other biological parameters in obese and diabetic patients. Endocrine 2014,46(3):674-7. 10.1007/s12020-014-0170-9
13. de la Iglesia R, Lopez-Legarrea P, Crujeiras AB, Pardo M, Casanueva FF, Zulet MA, Martinez JA: Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clin Endocrinol (Oxf) 2014,81(2):306-11. 10.1111/cen.12383
14. Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Belen CA, Seoane LM, Casanueva FF, Pardo M: FNDC5/irisin is not only a myokine but also an adipokine. PLoS One 2013,8(4):e60563. 10.1371/journal.pone.0060563
15. Peter PR, Park KH, Huh JY, Wedick NM, Mantzoros CS: Circulating irisin levels are not affected by coffee intake: a randomized controlled trial. PLoS One 2014,9(4):e94463. 10.1371/journal.pone.0094463
16. Hee PK, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS: Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013,98(12):4899-907. 10.1210/jc.2013-2373
17. Yan B, Shi X, Zhang H, Pan L, Ma Z, Liu S, Liu Y, Li X, Yang S, Li Z: Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS One 2014,9(4):e94235. 10.1371/journal.pone.0094235
18. Guilherme A, Virbasius JV, Puri V, Czech MP: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008,9(5):367-77. 10.1038/nrm2391
19. Handschin C, Spiegelman BM: The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 2008,454(7203):463-9. 10.1038/nature07206
20. Yan J, Feng Z, Liu J, Shen W, Wang Y, Wertz K, Weber P, Long J, Liu J: Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: ameliorating effects of (-)-epigallocatechin-3-gallate. J Nutr Biochem 2012,23(7):716-24. 10.1016/j.jnutbio.2011.03.014
21. Xiang L, Xiang G, Yue L, Zhang J, Zhao L: Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis 2014,235(2):328-33. 10.1016/j.atherosclerosis.2014.04.036
22. Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, Srbecky M, Imrich R, Kyselovicova O, Belan V, Jelok I, Wolfrum C, Klimes I, Krssak M, Zemkova E, Gasperikova D, Ukropec J, Ukropcova B: Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol 2014,592(Pt 5):1091-107.
23. Zhang M, Chen P, Chen S, Sun Q, Zeng QC, Chen JY, Liu YX, Cao XH, Ren M, Wang JK: The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci 2014,18(11):1567-72.
24. Yuksel MA, Oncul M, Tuten A, Imamoglu M, Acikgoz AS, Kucur M, Madazli R: Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract 2014,104(1):171-5. 10.1016/j.diabres.2013.12.025
25. Kuzmicki M, Telejko B, Lipinska D, Pliszka J, Szamatowicz M, Wilk J, Zbucka-Kretowska M, Laudanski P, Kretowski A, Gorska M, Szamatowicz J: Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol 2014,30(9):636-9. 10.3109/09513590.2014.920006
26. Ebert T, Stepan H, Schrey S, Kralisch S, Hindricks J, Hopf L, Platz M, Lossner U, Jessnitzer B, Drewlo S, Bluher M, Stumvoll M, Fasshauer M: Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery. Cytokine 2014,65(2):153-8. 10.1016/j.cyto.2013.11.009
27. Piya MK, Harte AL, Sivakumar K, Tripathi G, Voyias PD, James S, Sabico S, Al-Daghri NM, Saravanan P, Barber TM, Kumar S, Vatish M, McTernan PG: The identification of irisin in human cerebrospinal fluid: influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab 2014,306(5):E512-8. 10.1152/ajpendo.00308.2013
28. Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A, Marini MA, Perticone F: High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 2014,51(5):705-13. 10.1007/s00592-014-0576-0
29. Crujeiras AB, Zulet MA, Lopez-Legarrea P, de la Iglesia R, Pardo M, Carreira MC, Martinez JA, Casanueva FF: Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism 2014,63(4):520-31. 10.1016/j.metabol.2013.12.007
30. Al-Daghri NM, Alkharfy KM, Rahman S, Amer OE, Vinodson B, Sabico S, Piya MK, Harte AL, McTernan PG, Alokail MS, Chrousos GP: Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. Eur J Clin Invest 2014,44(2):119-24. 10.1111/eci.12196
31. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012,142(7):1592-609. 10.1053/j.gastro.2012.04.001
32. Polotsky AJ, Allshouse A, Crawford SL, Harlow SD, Khalil N, Santoro N, Legro RS: Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women. J Clin Endocrinol Metab 2012,97(6):E868-77. 10.1210/jc.2011-3357
33. Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS: Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism 2014,63(10):1265-71. 10.1016/j.metabol.2014.06.001
34. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, Han CK, Zhuang XJ, Lu Y, Li XJ, Yang SY, Li XY: Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2013,59(3):557-62. 10.1016/j.jhep.2013.04.030
35. Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS: Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014,63(2):207-17. 10.1016/j.metabol.2013.09.013
36. Choi ES, Kim MK, Song MK, Kim JM, Kim ES, Chung WJ, Park KS, Cho KB, Hwang JS, Jang BK: Association between Serum Irisin Levels and Non-Alcoholic Fatty Liver Disease in Health Screen Examinees. PLoS One 2014,9(10):e110680. 10.1371/journal.pone.0110680
37. Chang CL, Huang SY, Soong YK, Cheng PJ, Wang CJ, Liang IT: Circulating irisin and GIP are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab 2014,99(12):E2539-48. 10.1210/jc.2014-1180
38. Wen MS, Wang CY, Lin SL, Hung KC: Decrease in irisin in patients with chronic kidney disease. PLoS One 2013,8(5):e64025. 10.1371/journal.pone.0064025
39. Ebert T, Focke D, Petroff D, Wurst U, Richter J, Bachmann A, Lossner U, Kralisch S, Kratzsch J, Beige J, Bast I, Anders M, Bluher M, Stumvoll M, Fasshauer M: Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol 2014,170(4):501-6. 10.1530/EJE-13-1053
40. Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, Filippaios A, Mantzoros CS: Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporos Int 2014,25(5):1633-42. 10.1007/s00198-014-2673-x
41. Singhal V, Lawson EA, Ackerman KE, Fazeli PK, Clarke H, Lee H, Eddy K, Marengi DA, Derrico NP, Bouxsein ML, Misra M: Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates. PLoS One 2014,9(6):e100218. 10.1371/journal.pone.0100218